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Abstract
Ductal adenocarcinoma of the pancreas is one of the most aggressive forms of cancer, with only a minority of
cases being resectable at the moment of their diagnosis. The accurate detection and characterization of pancreatic
carcinoma is very important for patient management. Multidetector-row computed tomography (MDCT) has
become the cross-sectional modality of choice in the diagnosis, staging, treatment planning, and follow-up of
patients with pancreatic tumors. However, approximately 11% of ductal adenocarcinomas still remain undetected at
MDCT because of the lack of attenuation gradient between the lesion and the adjacent pancreatic parenchyma. In
this systematic literature review we investigate the current evolution of the CT technique, limitations, and
perspectives in the evaluation of pancreatic carcinoma.
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Background
Pancreatic adenocarcinoma is one of the most aggressive
forms of cancer. It is the fourth most common cause of
cancer-related mortality worldwide. The prognosis of pan-
creatic cancer is still bleak, as the 5-year survival rate is
less than 5% and the mortality rate has not declined over
the last few decades, with an increasing global incidence
of nearly 340,000 in 2012. The incidence rate near equal-
ing that of its mortality rate [1]. At presentation, about
40% of patients with pancreatic cancer are diagnosed with
metastatic disease (stage IV) and 40% are diagnosed with
locally-advanced pancreatic cancer (LAPC) [1, 2].
The accurate characterization of pancreatic adenocar-
cinoma is very important for patient management. Com-
puter tomography (CT) and magnetic resonance
imaging (MRI) are the most important modalities for
evaluating pancreatic lesions. A precise diagnosis of pan-
creatic tumor is not always simple because the tumor
can have atypical imaging features and many other dis-
orders may mimic pancreatic adenocarcinoma [3, 4].
Multidetector row (MD) CT has become the modality of
choice in the preoperative diagnosis and staging of the
disease and in treatment planning and follow-up in pa-
tients with pancreatic tumors [5]. Although many stud-
ies have investigated the effect of different techniques of
contrast medium injection for improving the enhance-
ment of the pancreas and peripancreatic vasculature
during the pancreatic parenchymal phase [6–10], ap-
proximately 11% of ductal adenocarcinomas remain
undetected at MDCT. This is because of the lack of a
visible attenuation difference between the tumor and
the adjacent pancreatic parenchyma. In these cases,
recognition secondary signs (e.g. main pancreatic duct
dilatation or the interrupted duct sign) becomes
mandatory to detect the lesion [11]. In this review we
investigate the evolution of the MDCT technique, limi-
tations, and future prospects in the evaluation of pan-
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Materials and Methods
Data for this review were identified by searches of the
PubMed database using a multimodal strategy. The
following search terms were employed: CT in pancreatic
cancer, functional CT in pancreatic cancer, CT in ad-
vanced pancreatic cancer, CT in advanced pancreatic
adenocarcinoma after chemotherapy. The inclusion cri-
teria were: clinical study evaluating pancreatic adenocar-
cinoma, clinical study evaluating new functional imaging
criteria in the CT study of patients with pancreatic
adenocarcinoma, and clinical study evaluating follow-up
after chemotherapy of patients with advanced pancreatic
adenocarcinoma. Articles published in the English lan-
guage from January 2003 to June 2016 were included.
The references of these articles were also analyzed to
identify original studies that were not identified by the
search of the data. Exclusion criteria unavailability of full
text and absence of original research data (reviews, edi-
torials, case reports, etc.).
Results
A Pubmed search yielded 1821 articles for key CT in
pancreatic cancer, 129 articles for functional CT in pan-
creatic cancer, 514 articles for CT in advanced pancre-
atic cancer, 77 articles for CT in advanced pancreatic
adenocarcinoma after chemotherapy. Among the total
number of 2541 articles, 2408 were excluded because of
unmatching the inclusion criteria. In the end, there were
133 articles: 58 for CT in pancreatic cancer, 25 for func-
tional CT in pancreatic cancer, 38 for CT in advanced
pancreatic cancer, and 12 for CT in advanced pancreatic
adenocarcinoma after chemotherapy. Among these, 96
articles corresponded to more than one criterion so 37
articles were included at the end (Fig. 1).
Discussion
MDCT has become the modality of choice in the pre-
operative diagnosis and staging and in treatment plan-
ning and follow-up of patients with pancreatic tumors
[5]. Since its introduction in clinical practice, volumetric
CT scanning has revolutionized pancreatic imaging, al-
though the greatest benefits have occurred with the de-
velopment of MDCT. This basically included short
acquisition times, thin sections in a single-breath hold,
retrospective calculation of thinner or thicker sections
from the same raw data, and improved 3D post-
processing [12]. The detection of tumor tissue and
visualization of pancreas and vessel infiltration is needed
so as to define when a tumor is resectable [12]. To
visualize organ infiltration (Figs. 2 and 3) a good contrast-
to-noise ratio is mandatory. To diagnose vessel infiltration,
the optimal imaging phase must be timed (Fig. 4) [13].
The enhancement kinetics of the normal pancreas fol-
lows arterial dynamics. There is a longer delay necessary
to increase the enhancement of the interstitial spaces of
the organ of interest, and hence to increase the contrast
to the ductal system and the lesion-to-background con-
trast for hypovascular pancreatic adenocarcinomas. Pan-
creatic imaging thus also benefits from high iodine flux
and accurate scan timing relative to the arrival of contrast
media in the abdominal aorta but also improves with lar-
ger contrast medium volumes. Scan timing is critical, and
best lesion-to-background contrast is achieved approxi-
mately 20 to 25 s after contrast medium arrival in the
aorta (for injection durations of 30 s, and scan times of ap-
proximately 5 s) [13].
Pancreatic parenchyma study should be carried out
with a quadruple-phase scanning protocol, including
unenhanced, arterial, pancreatic parenchymal, and portal
venous phases. However, according to Fletcher [14], the
acquisition of images in the arterial phase is not neces-
sary in the detection and staging of pancreatic adenocar-
cinoma. The acquisition of images in the pancreatic
phase is adequate to detect pancreatic tumor because in
this phase tumor-to-gland attenuation differences are
greatest. The images obtained during the hepatic phase
allow a tumor detection rate nearly equivalent to that of
the images obtained during the pancreatic phase [14].
Additionally, hepatic-phase images most accurately de-
pict vascular invasion [14]. So, to guarantee the most
effective rate of lesion detection, CT images must be
acquired during the pancreatic parenchymal phase when
the maximum difference in attenuation is attained
between typically poorly vascularized pancreatic tumors
and vividly enhancing pancreatic parenchyma [14].
Current MDCT protocols maximize the attenuation
differences between the hypovascular tumor and the sur-
rounding parenchyma [15]. However, there is an 11% of
pancreatic adenocarcinoma being isoattenuating (Fig. 5)
Fig. 1 Included and excluded studies in systematic review
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to the pancreatic parenchyma [16]. Consequently, many
studies have investigated the effect of techniques for in-
jection of contrast media on improving the enhancement
of the pancreas and peripancreatic vasculature during
the pancreatic parenchymal phase [6–10]. To improve
the conspicuity of pancreatic tumor and reduce radiation
dose, Marin et al. [10] evaluated the so called the low-
tube-voltage, high-tube-current CT technique. These
researchers demonstrated that, compared with a high-
tube-voltage CT protocol (140 kVp), a low-tube-voltage
(80 kVp), high-tube current (675 mA) technique has the
potential to improve the enhancement of the pancreas
and peripancreatic vasculature, increasing tumor conspi-
cuity and reducing patient radiation dose during the
pancreatic parenchymal phase. Nonetheless, these im-
provements come at the cost of decreased perceived
image quality (primarily the result of increased noise)
beyond what most clinical radiologists would consider
acceptable [10]. Dual-energy CT techniques may be used
to distinguish substances such as iodine, calcium and
uric acid crystals from soft tissues. The use of dual-
energy CT has potential clinical implications for imaging
of the pancreas [10, 17–25]. Owing to increased photo-
electric absorption and less Compton scatter at the
lower photon energies, the attenuation of contrast ma-
terial is greater at 80 kVp than at 120 or 140 kVp. The
closer the energy level is to the K edge of a substance
such as iodine, the more the substance attenuates. The
term K edge refers to the spike in attenuation that oc-
curs at energy levels just greater than that of the K-shell
binding because of the increased photoelectric absorp-
tion at these energy levels. K edge values vary for each
element, increasing as the atomic number increases.
With current dual-energy CT technology, the two ener-
gies most frequently employed are 80 kVp and 140 kVp.
Because the K edge of iodine (33.2 keV) is closer to 80
kVp than it is to 140 kVp, the attenuation of iodine-
containing substances is substantially higher at 80 kVp
[17]. According to Patel et al. [18] Single-source, dual-
energy MDCT could offer better ability to detect hypo-
vascular pancreatic adenocarcinomas at lower viewing
energy levels during the pancreatic phase of imaging.
Consequently the number of “under detected”, early-
stage lesions or isoattenuating tumors would decrease.
Macari et al. evaluate the attenuation and conspicuity of
pancreatic neoplasms and the pancreatic duct at dual-
energy dual-source CT performed at 80 kVp compared
with the more typical 120 kVp. The study showed that
in comparison with a weighted-average 120-kVp data
set, generation of pure 80-kVp data improves differenti-
ation of attenuation values between malignant tumors of
the pancreas and normal pancreas and may increase the
conspicuity of nearly isoattenuating and small pancreatic
adenocarcinomas [19]. Zamboni et al. [20] tested a
single-energy low-voltage CT protocol for pancreatic
adenocarcinoma to compare an 80 kV arterial phase scan
Fig. 2 CT scan in axial plane (a) and coronal plane, Multiplanar Reconstruction-MPR (b), during pancreatic phase of dynamic contrast study.
Body-tail adenocarcinoma (arrow)
Fig. 3 CT scan in axial plane (a) and coronal plane, MPR (b), during portal phase of dynamic contrast study. Tail pancreatic adenocarcinoma that
infiltrates vascular hilum of the spleen
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protocol with a 120 kV protocol, with regard to lesion con-
spicuity, image quality and radiation dose, both on a pa-
tient population and on phantoms. They demonstrated
that the use of a low voltage technique for pancreatic phase
scanning can increase even more the conspicuity of the
tumor in significant dose reduction while maintaining an
acceptable image quality [10, 17–25].
Perfusion CT (CTp) is a clinical technique that can be
used to provide maps and obtain quantitative measure-
ments of various hemodynamic parameters on the basis
of the linear relationship between CT enhancement and
iodinated contrast material concentration [26–33]. Some
study evaluated perfusion CT parameters, such as the
volume transfer constant (Ktrans) between blood plasma
and extracellular extravascular space and the blood vol-
ume calculated from dynamic CT data, or median peak
enhancement intensity and median blood volume can be
used to identify, to characterize and to evaluate the
response of pancreatic cancer to chemo-radiotherapy
[26–33]. Scialpi et al. [26] evaluated the effectiveness of
CTp imaging to detect small (≤2 cm) pancreatic adeno-
carcinoma. These authors showed that the quantitative
analysis of the enhancement for pancreatic adenocarcin-
oma and surrounding parenchyma may be considered in
order to increase the sensitivity of CT in the detection
of small tumor. Zamboni et al. [27] evaluated the rule of
time-density curve morphology for the differential diag-
nosis of solid pancreatic lesions showed that morphology
of the time-density curves obtained from serial scans
after contrast medium injection could be used to aid in
the differential diagnosis between normal parenchyma,
tumors and atrophic parenchyma. Curve morphology B
(Fig. 6), with no washout in the last portion of the curve
corresponds to adenocarcinoma, while curve morph-
ology C (Fig. 6), with at least some washout in the last
portion of the curve, corresponds to chronic pancrea-
titis. Yamada et al. [28] reported the use of time-density
curves obtained from triphasic CT in the differentiation
between carcinoma and mass-forming chronic pancrea-
titis. They concluded that pancreatic adenocarcinoma
shows an increasing contrast enhancement pattern,
while chronic pancreatitis shows an early-washout pat-
tern. Delrue et al. demonstrated the feasibility of CTp in
patients with a pancreatic pathologies and showed that
CTp is more capable to differentiate the pancreatic
disorders, compared to density measurements alone,
since no significant differences in perfusion values were
found between acute/chronic pancreatitis and pancreatic
adenocarcinoma, so differential diagnosis based only on
CTp data remains difficult [29]. Functional imaging from
CTp may add useful information on tumor aggressive-
ness affecting treatment strategy and patient manage-
ment. D’Onofrio et al. evaluated the CTp features of
locally advanced pancreatic ductal adenocarcinomas and
assessed whether these features correlate with the tumor
grading at pathology, showed that CTp can predict
tumor grade of pancreatic adenocarcinoma. In particular,
median peak enhancement intensity and median blood
volume proved their efficiency in identifying high grade
pancreatic adenocarcinoma [30]. Nishikawa et al. [31]
investigate the relationship between prognosis and per-
fusion in the tissue surrounding cancer. This study
proven a significant correlation between area under the
curve of peritumoral tissue (AUCPTT) or blood flow of
peritumoral tissue (BFPTT) and survival days from the
date on which perfusion CT was performed: higher
AUCPTT or BFPTT values were associated with shorter
survival. While it has not been demonstrated a
Fig. 4 Maximum Intensity Projection (MIP); arrow shows
vascular infiltration
Fig. 5 CT scan in axial plane during pancreatic phase of dynamic
contrast study. Isodense pancreatic adenocarcinoma (arrow)
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significant correlation between the BF of tumor or AUC
of tumor with patient survival. These findings suggest
that prognosis is related to increased perfusion in tissue
surrounding cancer [31]. Park et al. [32] reported that
decreased tumor permeability measured by CTp is re-
lated to chemosensitivity: pancreatic tumors with high
pretreatment Ktrans values indicating higher intratu-
moral flow tended to respond better to the neoadjuvant
chemotherapy. So, CTp may be used to predict the
tumor response of neoadjuvant chemotherapy and radi-
ation therapy in patients with pancreatic cancer [32].
CTp data can not only be markers which allow to dis-
criminate responders from non-responders patients in
the course of chemotherapy, but they can also be helpful
in the prediction of potential postoperative complica-
tions: Sugimoto et al. [33] evaluated risk assessment for
postoperative pancreatic fistula after pancreaticoduode-
nectomy using perfusion CT and showed that patients
who developed fistulas showed a higher arterial flow and
shorter mean transit time in the CTp profile, that
reflected a lower main pancreatic duct ratio, lower fat
ratio, lower fibrosis ratio, higher lobular ratio, and lower
vessel density in the histological assessment of the pan-
creatic stump. Therefore, CTp may enable preoperative,
objective, and quantitative assessment of the risk of
complications and allow surgeons to choose appropriate
countermeasures against postoperative pancreatic fistula
[33]. Klauß et al. [34] evaluated the feasibility of dual-
energy CT (DECT)-perfusion of pancreatic carcinomas
for assessing the differences in perfusion, permeability
and blood volume of healthy pancreatic tissue and histo-
pathologically confirmed solid pancreatic carcinoma.
The study showed that perfusion, permeability and
blood volume values were significantly lower in pancre-
atic carcinomas compared to healthy pancreatic tissue;
so the use of DECT improves the accuracy of CTp of
the pancreas by fully exploiting the advantages of en-
hanced iodine contrast at 80 kVp in combination with
the noise reduction at 140 kVp. Therefore using dual-
energy perfusion data could improve the delineation of
pancreatic carcinomas [34].
To reduce radiation dose and increase conspicuity of
tumor Brook et al. [35] evaluated the Split-bolus tech-
nique during the study of the pancreas. Split-bolus con-
trast material administration is based on injection of
various amounts of contrast material in two or three
parts with a variable pause while scanning is performed
only once, so to obtain a combined-phase images in a
single scan. In this study has been demonstrated that
with a single combined phase, split-bolus spectral CT
examination resulted in vascular, liver, and pancreatic at-
tenuation and pancreatic tumor conspicuity equal to or
higher than those obtained with a standard combination
of two-phase pancreatic CT, with a 43% reduction in the
radiation dose [35].
To identify and characterize a pancreatic lesion is es-
sential not only the phase of study but also the concen-
tration, the injection flow rates and volumes. Yanaga et
al. [36] evaluated a protocol with a fixed contrast mater-
ial injection dose and one with a dose tailored to patient
body weight and has been demonstrated that with the
fixed contrast material dose protocol, pancreatic en-
hancement during the pancreatic parenchymal phase
was significantly worse in the heavier patients (body
weight of 60 kg or greater) than in the lighter patients
(body weight of less than 60 kg). On the other hand,
Fig. 6 a Type A curve wash-in followed by wash-out (normal parenchyma); b type B curve-low wash-in, followed by plateau or increasing density,
without wash-out (adenocarcinoma); c type C curve-low wash-in, followed by at least a slight wash-out (chronic pancreatitis); d type D curve-
brisk wash-in, followed by clear wash-out (endocrine tumor)
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there was no significant difference between the two weight
groups with the protocol in which contrast material dose
was tailored to patient weight. So CT protocols that deliver
a contrast material dose tailored to patient weight at a fixed
injection duration yield satisfactory pancreatic enhance-
ment in patients of different body weights [36] and that in-
creases the tumor detection. Liu et al. [37] demonstrated
that although the pancreas, pancreatic malignancies and
other abdominal organs are more enhanced in higher iod-
ine concentration group in arterial and/or portal venous
phase, the detection and demarcation of pancreatic adeno-
carcinomas was not found to improve with the higher iod-
ine concentration so as demonstrated also by Fenchel et al.
[38]. These results demonstrate that where it has to use
contrast agents at low dose, as in patients with renal im-
pairment, there is not the risk of identifying a pancreatic
tumor [37, 38]. Then for an accurate study of the pancre-
atic parenchyma it is more important than a correct dose
of contrast, considering the patient’s body weight, which is
not the concentration of the contrast [36–38].
Although radical resection is still the only curative treat-
ment for pancreatic cancer, it is generally accepted that a
multimodality strategy is necessary for its management,
because at the time of diagnosis about 40% of patients
with pancreatic cancer are diagnosed with metastatic dis-
ease (stage IV) and the remaining 40% are diagnosed with
LAPC [1, 2, 39]. After neoadjuvant chemo-radiotherapy
(CRT) or ablation therapy, CT is usually used to evaluate
treatment response and to restage tumors. CRT, especially
radiation therapy, may induce fibrosis, which confounds
viable tumor analysis at CT reducing preoperative staging
accuracy [40]. Also the study of Cassinotto et al. [41] con-
firmed the decrease in the diagnostic performance of the
CT to reevaluate resectability after neoadjuvant therapy of
pancreatic tumor. Morgan [42] demonstrated that the CT
sensitivity for prediction of resectability tends to be lower
for patients with locally advanced pancreatic cancer that
has been downstaged by neoadjuvant therapy than for
controls who did not receive preoperative therapy. In pa-
tients undergoing chemo radiotherapy the most limits of
CT is differentiating a residual tumor from the fibro-in-
flammatory tissue, so other techniques are needed to
optimally evaluate the tumor response. MRI with diffu-
sion sequencing and dynamic analysis would enable to
differentiate between tumor tissue and edematous fi-
brosis [2, 4, 39]. Similarly, CTp could help provide
functional information and aid in the characterization
of residual tissue [32].
Conclusion
Although MDCT is the modality of choice in the pre-
operative diagnosis and staging and in treatment plan-
ning and follow-up of patients with pancreatic cancer,
there is an 11% of pancreatic adenocarcinoma is being
unrecognized. Therefore it is necessary to optimize the
technique, with a dose of the contrast medium adequate
to the weight of the patient, with a proper delay after ad-
ministration of the contrast medium. Parenchymal pan-
creatic phase is better than arterial phase. Dual-source,
dual-energy MDCT and CTp improve the detection of
pancreatic adenocarcinoma, increasing the conspicuity
of nearly isoattenuating, small lesions. CTp, additionally,
provides functional information and can aid in the as-
sessment of residual viable tumor tissue after CRT.
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